Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)

InMed Pharmaceuticals' FCF Margin history spans 5 years, with the latest figure at 289.72% for Q4 2025.

  • For Q4 2025, FCF Margin fell 6465.0% year-over-year to 289.72%; the TTM value through Dec 2025 reached 164.69%, down 1377.0%, while the annual FY2025 figure was 157.14%, 500.0% down from the prior year.
  • FCF Margin reached 289.72% in Q4 2025 per INM's latest filing, down from 143.52% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 29.85% in Q2 2023 to a low of 1728.88% in Q1 2022.
  • Average FCF Margin over 5 years is 408.46%, with a median of 164.96% recorded in 2024.
  • Peak YoY movement for FCF Margin: surged 156865bps in 2023, then tumbled -7605bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 1252.16% in 2021, then skyrocketed by 54bps to 577.52% in 2022, then skyrocketed by 74bps to 149.02% in 2023, then plummeted by -51bps to 225.07% in 2024, then decreased by -29bps to 289.72% in 2025.
  • Per Business Quant, the three most recent readings for INM's FCF Margin are 289.72% (Q4 2025), 143.52% (Q3 2025), and 136.31% (Q2 2025).